|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Navigating Non-Metastatic Castration-Resistant Prostate Cancer Treatment in the PSMA PET Era |
Neal Shore, MD, FACS
Zach Klaassen discusses the evolving landscape of non-metastatic castration-resistant prostate cancer (nmCRPC) with Neal Shore. They delve into the significant impact of PSMA PET scans on diagnosing and treating nmCRPC. |
|
|
|
|
|
|
|
|
|
|
| Advancing Prostate Cancer Care: The EMBARK Study and Implications for Clinical Practice |
| Stephen Freedland, MD |
| Daniel George and Stephen Freedland delve into the EMBARK study, a trial on Enzalutamide for high-risk non-metastatic biochemical recurrence of prostate cancer. They explore the approach of using Enzalutamide, both in combination with Leuprolide and as monotherapy, highlighting its significant impact on metastasis-free survival. |
|
|
|
|
|
|
|
|
|
|
|
|
Redefining Low-Volume Metastatic Prostate Cancer in the Era of PSMA PET Imagin
|
|
Oliver Sartor, MD
|
| Oliver Sartor discusses his approach to treating low-volume metastatic prostate. Dr. Sartor emphasizes the importance of molecular imaging, particularly PSMA PET, to define low-volume and oligometastatic disease accurately.
|
|
|
|
|
|
|
|
|
|
|
|
| How to Manage Patients with Low-Volume on Conventional and High-Volume on Next-Generation Imaging
|
| Dana Rathkopf, MD
|
| Dana Rathkopf discussed managing mHSPC patients with low-volume disease on conventional imaging but high-volume disease on next-generation imaging. She highlighted the complexity added by next-generation imaging, noting its higher accuracy but also the potential for indeterminate findings and patient distress. Dr. Rathkopf emphasized the importance of using clinical subgroups to guide treatment decisions, advising caution in directly extrapolating PET findings to conventional imaging-based treatment plans.
|
|
|
|
|
|
| PSMA PET in Patients with Prostate Cancer – Gained Insights from Eight Years of Reimbursable Imaging |
| Dan Cohen, Ph.D. |
| Dan Cohen presents on the insights gained from eight years of reimbursable PSMA PET imaging for prostate cancer in Israel. He highlights the increased accuracy and utility of PSMA PET in identifying prostate cancer lesions, guiding treatment selection, and monitoring disease progression. Dr. Cohen emphasizes understanding the different PSMA ligands, their pharmacokinetics, and their role in modifying clinical workflows, especially in accurately reporting and managing prostate cancer at various stages. |
|
|
|
|
|
|
|
|
|
|
| 3TMPO: Prognostic Value of FDG, PSMA, and DOTATATE Uptake on PET Imaging in mCRPC |
| Frederic Pouliot, MD, Ph.D. |
| Frederic Pouliot presents findings from the 3TMPO study on the prognostic value of FDG, PSMA, and DOTATATE uptake in mCRPC. The study revealed that patients with FDG+/PSMA- lesions had significantly shorter overall survival compared to those without such lesions, and the prognosis worsened further for those with DOTATATE+ lesions. |
|
|
|
|
|
| Impact of Pre-operative PSMA PET/CT for Men with cN0M0 Conventional Imaging and pN+ Prostate Cancer: Results from a Multicenter Study
|
| Gabriele Montefusco, MD
|
| Gabriele Montefusco presented a multicenter study on the impact of pre-operative PSMA PET/CT for men with cN0M0 conventional imaging who were found to have pN+ prostate cancer at radical prostatectomy. The study, which included 1,163 patients, found that men with cN+ disease on PSMA PET/CT had a significantly higher risk of systemic progression compared to those with cN0 disease on both PSMA PET/CT and conventional imaging.
|
|
|
|
|
|
| Biochemical Recurrence in Patients with Prostate Cancer after Primary Definitive Therapy: Next-Generation Imaging and Treatment Based on Risk Stratification - Beyond the Abstract
|
| Judd Moul, MD, and Neal Shore, MD
|
| Biochemical recurrence after primary definitive treatment for prostate cancer occurs in about one-third of patients and is defined by rising PSA levels post-treatment. Next-generation imaging technologies, such as PET radiotracers, offer improved sensitivity for detecting BCR at lower PSA values compared to conventional imaging. There is a need for risk-stratified management and personalized treatment strategies for BCR, as current guidelines lack consensus on the most effective treatments, but NGI shows promise in better-informing treatment decisions and improving patient outcomes.
|
|
|
|
|
|
|
|
|
|
|
